PVLAPalvella Therapeutics, Inc.
Price
+139%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, growth steady, the market undecided.
We are a clinical-stage biopharmaceutical company whose vision is to become the leading rare disease biopharmaceutical company focused on developing and, if approved, commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. We envision a future treatment paradigm in which individuals suffering from serious, rare skin diseases and vascular malformations, and the physicians treating those diseases, have significantly improved treatment options which address the underlying causes of those diseases.
In the company’s own words · 10-K filed Mar 31, 2026 · SEC EDGAR
The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Jul 14, 2026On July 14, 2026, Palvella Therapeutics, Inc. (the “Company”) posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time.Other event · Form 8-K
- Jun 30, 2026On June 29, 2026 (the “Appointment Date”), the Board of Directors (the “Board”) of Palvella Therapeutics, Inc. (the “Company”) increased the size of the Board from seven to eight members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Matthew Pauls, to serve as a Class I …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry